Regeneron Pharmaceuticals Inc (REGN), Pharmacyclics, Inc. (PCYC): Is There Pipeline Potential in These Biotech Stocks?

Sarepta Therapeutics Inc (NASDAQ:SRPT)’s eterplirsen skips the exon 51, which is a process that allows Sarepta to up-regulate or down-regulate specific genes and proteins associated with a disease. The company is also using its exon-skipping technology on exons 45, 50, and 53 in preclinical studies to treat other rare diseases. However, the company also has a pipeline to treat infectious diseases, and data surrounding its Phase 1 candidate AVI-7288 could be the next catalyst.

AVI-7288 is being developed to treat the very deadly Marburg virus. In a previous study, AVI-7288 demonstrated a survival range between 83% and 100% in four different cohorts. The placebo group had a zero percent survival.

As a result, the company is progressing, and was recently granted an FDA Fast Track designation. If further testing supports the previous study, AVI-7288 could see a speedy FDA approval. In addition, Sarepta Therapeutics Inc (NASDAQ:SRPT) would validate its infectious disease pipeline much like its exon-skipping approach.

Conclusion

In biotechnology, one product may grab investors’ attention — but the pipeline keeps that attention.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s Dupilumab treats asthma, and has already shown strong clinical data to-date. Dupilumab’s peak sales could push Regeneron’s stock higher, making it an important drug to follow. As for Pharmacyclics, Inc. (NASDAQ:PCYC) and Sarepta Therapeutics Inc (NASDAQ:SRPT), both have products in early development, but promising nonetheless, and will be interesting to follow in the years ahead.

Sherrie Stone owns Regeneron. The Motley Fool has no position in any of the stocks mentioned.

The article Is There Pipeline Potential in These 3 Biotech Stocks? originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.